Document Detail

Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.
MedLine Citation:
PMID:  20801540     Owner:  NLM     Status:  MEDLINE    
BACKGROUND & AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus. Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular iron export and iron binding to transferrin.
RESULTS: A novel homozygous ceruloplasmin gene mutation, c.2554+1G>T, was identified as the cause of aceruloplasminemia in three affected siblings. Two siblings presented with movement disorders and diabetes. Complementary DNA sequencing showed that this mutation causes skipping of exon 14 and deletion of amino acids 809-852 while preserving the open reading frame. Western blotting of liver extracts and sera of affected patients showed retention of the abnormal protein in the liver. Aceruloplasminemia was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload. Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with deferasirox, which was also associated with reduced insulin demands. During short term treatment there was no clinical or imaging evidence for significant effects on brain iron overload.
CONCLUSIONS: Aceruloplasminemia can show an incomplete clinical penetrance but is invariably associated with iron accumulation in the liver and in the brain. Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of iron overload. Iron chelation with deferasirox was effective in mobilizing hepatic iron but has no effect on brain iron.
Armin Finkenstedt; Elisabeth Wolf; Elmar Höfner; Bethina Isasi Gasser; Sylvia Bösch; Rania Bakry; Marc Creus; Christian Kremser; Michael Schocke; Milan Theurl; Patrizia Moser; Melanie Schranz; Guenther Bonn; Werner Poewe; Wolfgang Vogel; Andreas R Janecke; Heinz Zoller
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-04
Journal Detail:
Title:  Journal of hepatology     Volume:  53     ISSN:  1600-0641     ISO Abbreviation:  J. Hepatol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-02     Completed Date:  2011-02-24     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1101-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Department of Medicine II Gastroenterology and Hepatology, Medical University of Innsbruck, Innsbruck, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimicrobial Cationic Peptides / genetics
Benzoates / therapeutic use*
Brain / metabolism
Ceruloplasmin / deficiency,  genetics*,  metabolism
Iron / metabolism*
Iron Chelating Agents / therapeutic use*
Iron Metabolism Disorders / drug therapy,  genetics,  metabolism
Liver / metabolism
Middle Aged
Neurodegenerative Diseases / drug therapy,  genetics,  metabolism
RNA, Messenger / genetics,  metabolism
Triazoles / therapeutic use*
Reg. No./Substance:
0/Antimicrobial Cationic Peptides; 0/Benzoates; 0/Iron Chelating Agents; 0/RNA, Messenger; 0/Triazoles; 0/hepcidin; 7439-89-6/Iron; EC; V8G4MOF2V9/deferasirox

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hepatitis C virus entry and glucocorticosteroids.
Next Document:  Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with meth...